Amlexanox, a dual inhibitor of TBK1 and IKKε, downstream kinases in the STING pathway, has shown potential in animal models of obesity and type 2 diabetes. The gene discussed is TBK1; the disease is obesity due to melanocortin 4 receptor deficiency.